Skip to main
HUM

Humana (HUM) Stock Forecast & Price Target

Humana (HUM) Analyst Ratings

Based on 18 analyst ratings
Hold
Strong Buy 11%
Buy 22%
Hold 61%
Sell 6%
Strong Sell 0%

Bulls say

Humana has increased its 2025 earnings per share (EPS) estimate to $17.06, reflecting strong second-quarter results and revised guidance, signaling positive financial momentum. The company's focus on margin improvement initiatives is expected to drive year-over-year earnings growth in 2027, despite assumptions regarding static performance in its Stars rating system. Furthermore, Humana's competitive advantage is bolstered by its above-industry Medicare Advantage star ratings, positioning the firm favorably amid potential regulatory and reimbursement changes.

Bears say

Humana's financial outlook is negatively impacted by expectations of a slight decline in 2026 earnings per share (EPS) compared to 2025, primarily due to challenges related to its Medicare Advantage (MA) Stars ratings and competitive pressures. Additionally, the risks associated with increased MA utilization, inadequate reimbursement rates, declining membership in prescription drug plans (PDP), and slower growth in healthcare services are significant factors contributing to the company's uncertain future performance. Furthermore, management anticipates that investments required to support Stars recovery could lead to a potential shortfall of approximately 10% in fiscal year 2027 EPS estimates, highlighting the financial strain that may affect Humana's profitability.

Humana (HUM) has been analyzed by 18 analysts, with a consensus rating of Hold. 11% of analysts recommend a Strong Buy, 22% recommend Buy, 61% suggest Holding, 6% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Humana and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Humana (HUM) Forecast

Analysts have given Humana (HUM) a Hold based on their latest research and market trends.

According to 18 analysts, Humana (HUM) has a Hold consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $287.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $287.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Humana (HUM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.